ERBB2 and breast carcinoma: An exploratory analysis of the phase 2 DAISY trial in breast cancer reported that HER2 hemizygous deletion and SLX4 mutations likely underlie primary acquired resistance to trastuzumab deruxtecan (T-Dxd) [2].